Asimov’s mission is to advance humanity’s ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform – from cells to software – to design and manufacture next-generation therapeutics, including cell & gene therapies, through a combination of products, services, & collaborations. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million.


  • LV Edge System
    Routinely achieve lentiviral titers over 1E8 TU/mL for therapeutic GOI. Choose from a semi-stable packaging system or a fully-stable producer system....